ParaZero names new VP of Global Sales

ParaZero Technologies Ltd. reported a leadership change, appointing Ms. Bat-Sheva Noy as Vice President of Global Sales, effective March 8, 2026.

Rhea-AI Filing Summary

ParaZero Technologies Ltd. reported a leadership change, appointing Ms. Bat-Sheva Noy as Vice President of Global Sales, effective March 8, 2026. She brings over 20 years of commercial experience, including multiple senior roles at Pfizer Israel across rare diseases and cardiovascular product lines.

Her background spans strategic planning, national sales and marketing leadership, team development and cross-functional initiatives. ParaZero also states that this report is incorporated by reference into its existing Form S-8 and Form F-3 registration statements, meaning those securities filings now include this management update.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive appointment did ParaZero Technologies (PRZO) announce in this Form 6-K?

ParaZero Technologies appointed Ms. Bat-Sheva Noy as Vice President of Global Sales, effective March 8, 2026. The filing highlights her extensive commercial leadership background, particularly from senior roles at Pfizer Israel in rare diseases and cardiovascular sales and marketing.

What is Ms. Bat-Sheva Noy’s professional background before joining ParaZero Technologies (PRZO)?

Before joining ParaZero, Ms. Noy spent over two decades in pharmaceutical sales and leadership, primarily at Pfizer Israel. She led the rare diseases business unit from 2020 to 2025 and served as sales and marketing lead for the cardiovascular portfolio from 2017 to 2019.

What educational qualifications does ParaZero’s new VP of Global Sales, Ms. Noy, hold?

Ms. Noy holds an LL.B. in Law from The Academic Centre of Law and Science in Israel and a B.Sc. in Chemistry & Biology from Tel Aviv University. The filing also notes her service as an Optical Systems Instructor in the Israel Defense Forces’ electro-optics unit.

When does Ms. Bat-Sheva Noy’s appointment at ParaZero Technologies (PRZO) become effective?

Her appointment as Vice President of Global Sales is effective March 8, 2026. The Form 6-K states the Board approved the appointment on March 1, 2026, with the effective date following shortly after to formalize her executive role at the company.

How is this ParaZero Technologies (PRZO) Form 6-K used in the company’s SEC registrations?

The Form 6-K is incorporated by reference into ParaZero’s existing Form S-8 and Form F-3 registration statements. This means the information about the new executive appointment becomes part of those previously filed securities registration documents from the submission date of this report.

Does the ParaZero (PRZO) March 2026 Form 6-K include financial results or transaction details?

The March 2026 Form 6-K focuses on a management change, specifically appointing a new Vice President of Global Sales. It does not present financial results or major transaction details, instead updating corporate leadership information and linking it to existing registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of March 2026

Commission file number: 001-41760

ParaZero Technologies Ltd.

(Translation of registrant’s name into English)

1 Hatachana Street

Kfar Saba, 4453001, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

CONTENTS

On March 1, 2026, ParaZero Technologies Ltd. (the “Company”) appointed Ms. Bat-Sheva Noy as the Company’s Vice President of Global Sales, effective March 8, 2026.

Ms. Noy is an experienced executive with over 20 years of experience, bringing deep expertise in strategic planning, market access and cross-functional team leadership. From 2020 to 2025, Ms. Noy served as the business unit lead for rare diseases at Pfizer Israel, a subsidiary of Pfizer Inc. (NYSE: PFE), where she was responsible for strategy, team development and business performance and drove cross-functional initiatives and organizational growth. From 2017 to 2019, Ms. Noy served as the sales and marketing lead at Pfizer Israel where she led national sales and marketing operations for the cardiovascular portfolio, achieving global #1 performance and developed strategic brand plans based on market insights and strengthened collaborations with external stakeholders. Prior to these roles, Ms. Noy served in various sales and manager roles at Pfizer Israel from 2004 to 2017, and prior that, from 2002 to 2004, Ms. Noy was a sales representative at GSK Israel. Ms. Noy holds an LL.B. in Law from The Academic Centre of Law and Science (Israel), and a B.Sc. in Chemistry & Biology from Tel Aviv University (Israel). She also served as an Optical Systems Instructor in the Israel Defense Force’s electro-optics unit.

This Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-278268 and 333-285054) and Form F-3 (File Nos. 333-281443 and 333-275351), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ParaZero Technologies Ltd.
Date: March 2, 2026	By:	/s/ Ariel Alon
		Name:	Ariel Alon
		Title:	Chief Executive Officer

2